Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
about
Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.Characteristic clinical features of Aspergillus appendicitis: Case report and literature review.Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts.A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaClinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myeIncidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860
Q35894752-23DDB007-4581-440E-BB60-0889EE14B59DQ36316933-A36D9395-C978-4F8F-97FF-5717AF19FCDDQ41242339-04EC2F63-1C44-452B-AA16-FE925428F5A0Q48163223-235931EF-6B35-47BE-8BA3-BBE60913878EQ50584736-6AA610B0-DCDA-4B5A-ACB7-2BD0B15C4218Q51339494-A437FBC7-13DE-411F-A305-DDEA6C369CF1Q57292845-D082835A-16F9-4F74-B434-7CD123EEA164Q58761740-060D76E4-EF4F-4705-9A39-7A3F349770AEQ58767839-81FB64D1-334F-4877-8334-FD7A3889EA78
P2860
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
type
label
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
prefLabel
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@ast
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
P2093
P2860
P356
P1476
Risk and consequences of chemo ...... ce of duration of prophylaxis.
@en
P2093
Alex Kartashov
Andrew G Glass
Derek Weycker
Jason Legg
John Edelsberg
Rich Barron
P2860
P2888
P356
10.1186/1472-6963-14-189
P577
2014-04-27T00:00:00Z